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Structural evidence for the covalent modification
of FabH by 4,5-dichloro-1,2-dithiol-3-one (HR45)†
Alexander G. Ekström,a Van Kelly,a Jon Marles-Wright, b Scott L. Cockroft a and
Dominic J. Campopiano *a
We use mass spectrometry analysis and molecular modelling to
show the established antimicrobial inhibitor 4,5-dichloro-1,2-
dithiol-3-one (HR45) acts by forming a covalent adduct with the
target β-ketoacyl-ACP synthase III (FabH). The 5-chloro substituent
directs attack of the essential active site thiol (C112) via a Michael-
type addition elimination reaction mechanism.
Fatty acid biosynthesis is essential for cell viability and growth,
deriving fatty acids from the fundamental building block
acetyl-CoA. In eukaryotes, this process is facilitated by type I
fatty acid synthase (FAS I); a large, multi-domain enzyme con-
taining all required functionalities.1 In contrast, most bacteria
utilise a complex of proteins termed type II fatty acid synthase
(FAS II), whereby each functionality is carried out by a discreet
enzyme, between which the growing acyl chain is transported
by the acyl carrier protein (ACP).1 Substantial differences in
the architecture and chemistry carried out by FAS I and II
systems has led to significant interest in the bacterial pathway
as a target for new antibacterial compounds.
β-Ketoacyl-ACP synthase III (FabH) is the first condensing
enzyme in the FAS II pathway,2 and has attracted significant
attention as a target for novel antibiotic design.3–7 This ubiqui-
tous, highly conserved enzyme catalyses the cysteine-mediated,
Claisen-like condensation between malonyl-ACP and short
chain acyl-CoAs. Despite the suggestion that Gram-positive
bacteria can absorb and utilise exogenous fatty acids,8,9 FabH
is widely believed to be essential for cell viability.10 A few
natural product inhibitors of FAS II exist in the literature,11,12
but despite research efforts there are no FabH-specific inhibi-
tors approved for clinical use.
Of the natural products, the thiolactone antibiotic thiolacto-
mycin (TLM, Fig. 1) has selectivity for FAS II condensing
enzymes by mimicking malonyl-ACP binding.11,13 He et al.
used TLM as a starting point to develop potent FabH inhibi-
tors by searching the National Cancer Institute (NCI) database
for structurally similar molecules.3,14,15 The most potent hit
was 4,5-dichloro-1,2-dithiol-3-one (also referred to in the litera-
ture as HR45 and DDCP, Fig. 1). Subsequent structure–activity
relationship studies showed that the chlorine in the 5-position
was found to be essential for irreversible inhibition of FabH
isoforms from both Staphylococcus aureus (saFabH) and
Escherichia coli (ecFabH) with reported IC50 values of 156 nM
and 2.0 μM, respectively.15 The reported mode of inhibition
was inconclusive, and despite postulating covalent modifi-
cation via a Michael-type mechanism they were unable to
obtain data to support this hypothesis. This commercially
available 1,2-dithiol-3-one (CAS 1192-52-5) has since been fre-
quently reported as a positive control for FabH inhibition,16–21
and also has FDA approval as a slimicide additive in the paper
industry for food packaging (FDA docket number 99F-1423).
A less efficacious hit from the same study was HR12 (also
known as RWJ-3981, Fig. 1), an analogue of HR45 with a
phenyl group replacing the chlorine in the 4-position, with
reported IC50 values of 0.98 μM and 5.7 μM for saFabH and
ecFabH respectively.3,15 Interestingly, in a separate study HR12
was identified as a hit against E. coli uridine diphosphate-N-
acetyl glucosamine enolpyruvyl transferase (ecMurA), a
cysteine-dependent enzyme involved in the first committed
step of peptidoglycan cell wall biosynthesis.22
The mode of inhibition was speculated to be covalent
modification of the catalytic ecMurA C115 residue. Due to the
Fig. 1 HR45 and HR12, hits against saFabH and ecFabH from an NCI
database screen by He et al. based on thiolactomycin.15 HR12 identified
as a hit against ecMurA in a separate study.22
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lack of homology between saFabH and ecMurA, it is unlikely
that the HR45 mechanism is restricted to these two enzymes.15
The authors were unable to obtain supporting mass spec-
trometry (MS) data and suggested that the modification did
not survive the MS conditions. A key point to note was that the
inhibition could be reversed through reduction of the disulfide
by dithiothreitol (DTT).
The structure of HR45 suggests that the Michael-type accep-
tor nature of the cyclic α,β-unsaturated ketone could define it
as a pan assay interference compound (PAIN)23 with non-
specific activity towards nucleophilic amino acid residues.
Whilst PAINs are often removed from traditional small mole-
cule screens, it has been suggested that this should not be the
case when screening for antimicrobial activity.24 To begin our
study of the 1,2-dithiol-3-ones we conducted a simple model
reaction between HR45 and N-acetylcysteine (Fig. S1 and 2†).
The reaction was followed by 1H NMR, showing an immediate
shift in the pro-chiral CH2 group (Fig. S2†). Subsequent
13C
and 2D HMBC NMR experiments confirmed that the addition–
elimination had taken place at the 5-position (Fig. S2†). This
proposed mechanism is supported by Spartan modelling of
HR45, which indicated C-5 as the most electrophilic centre
(Fig. S3†). Encouraged by this data we set out to capture FabH-
bound adducts of HR45 by MS.
We elected to work with saFabH, an isoform with only one
catalytically essential cysteine residue, against which
HR45 had shown the highest activity.15 Recombinant saFabH
was isolated from E. coli and found to be gluconated, as is often
observed on N-terminal hexahistidine affinity tags.25 Removal
of the tag was essential to produce uncomplicated LC-MS
spectra of the intact protein (Fig. S8†). This resulted in well-
resolved MS data with a single peak for each charge state and a
deconvoluted mass of 34 063.7 Da that matched well with pre-
dicted values (Fig. 2a and Fig. S8†). Covalent modification of
saFabH by HR45 was rapid and quantitative in the absence of
reducing agent, accompanied with a shift of the deconvoluted
mass of +150 Da (Fig. 2b). This mass change is consistent with
the addition of HR45 with the loss of HCl. This data supports
our proposed mechanism, involving attack of the nucleophilic
cysteine residue followed by elimination of the ipso-chlorine
(Fig. S2†). The HR45 modification was quantitatively removed
by incubation with excess DTT (2 mM) for 15 min, resulting in
the native protein mass. We also treated the native saFabH
with the irreversible, cysteine-specific label N-ethylmaleimide
(NEM), which resulted in a mass shift of +125 Da, signifying
quantitative labelling of a single cysteine residue (Fig. 2c). The
NEM-modified sample was then incubated with HR45 for 3 h;
resulting in no further mass change (Fig. 2d). This indicates
that alkylation of C112 prevents the reaction of saFabH with
HR45 (Fig. 2d).
To further confirm modification of C112, HR45-modified
saFabH was digested with trypsin to generate peptide frag-
ments. As well as the absence of the ion corresponding to the
C112-containing tryptic peptide (103-VASMDQLAAC̲S-
GFMYSMITAK-123, predicted monoisotopic mass 2224.0036
Da, observed 1113.0042 Da [M + 2H]2+) in the control digest
(Fig. 3a), we also failed to detect a peptide corresponding to
the expected mass of the C112-HR45 adduct. This observation
was consistent with previous studies that attempted to detect
HR12 adducts.22 To discover the fate of the C112-containing
peptide, it was purified from a large-scale trypsin digest of
saFabH with activated thiol sepharose. After elution with
DTT, the peptide was desalted and resuspended in either
ammonium bicarbonate (pH 8.0) or ammonium acetate (pH
7.0) buffer and incubated in the presence or absence of HR45
to investigate the stability of the peptide and the HR45 adduct.
In ammonium acetate, both the unmodified and HR45-modi-
fied forms were observed at the predicted masses (Fig. 3a and
c), consistent with observations on the intact protein (Fig. 2b).
In contrast, in ammonium bicarbonate (Fig. 3b), the unmodi-
fied peptide was found to exist predominantly as a [M + 4H]4+
disulfide dimer. Perplexingly, upon incubation of the HR45-
modified form in ammonium bicarbonate (Fig. 3d) a new
signal appeared corresponding to a loss of 34 Da from the
unmodified peptide (predicted 2189.9837 Da, observed
1095.9991 Da [M + 2H]2+). Using CID tandem MS, we obtained
a fragmentation spectrum which we interpreted as the conver-
sion of C112 to dehydroalanine (Dha) (Fig. S7†). A small
amount of this Dha-containing peptide also formed from the
disulfide dimer at pH 8.0 (Fig. 3b).
This C112 to Dha conversion under typical tryptic digest
conditions may be the reason for previous failures to observe
Fig. 2 The LC-MS spectra (26+ charge state) of saFabH (a) unmodified
control, (b) protein incubated with HR45 for 30 min at RT resulting in
complete modification (+150 Da), (c) protein incubated with
N-ethylmaleimide (NEM) resulting in complete alkylation of the single
cysteine residue (+125 Da), and (d) NEM-alkylated protein incubated
with HR45 for 3 hours at RT resulting in no mass change.
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the covalent modification of saFabH and ecMurA by HR45 and
similar inhibitors. The alkaline hydrolysis pathway of 1,2-
dithiol-3-ones is a highly complex one.26 Although we do not
yet have sufficient data to speculate on the mechanism of the
C112-HR45 to Dha conversion, it is likely that one of the hydro-
lysis products facilitates the transformation, possibly by a
similar mechanism to other Dha formation chemistry.27
The instability of the adduct under standard trypsin digest
conditions led us to seek an alternative method. We digested
HR45-modified saFabH at pH 2.0 with pepsin, and identified
two peptic peptides in the unmodified control, AAC ̲SGF
and AAC ̲SGFMOx (MOX denotes oxidation of the M residue).
The extracted ion chromatogram (EIC, Fig. 4) shows the two
unmodified peptic fragments that are absent in the HR45-
modified sample. In the modified sample, two new signals
appear in the EIC with masses corresponding to AAC*SGF and
AAC*SGFMOx, where C* denotes a cysteine modification of
+150 Da, corresponding to addition of HR45 with the loss of
HCl. Clearly a chlorine atom is incorporated in the modified
peptides due to the distinctive isotope pattern (Fig. 4). CID
tandem MS was used to fragment AAC*SGFMOx, confirming
that the modification was indeed on the cysteine residue
(Fig. S6†). When similar pH-dependence experiments were
conducted on the intact saFabH-HR45 adduct, we observed no
evidence of dehydroalanine formation. In the intact protein,
C112 is located at the N-terminus of a long α-helix which
lowers the pKa of C112 from 8.8 to 7.2.
28,29 What impact this
environment has on the stability of the HR45 adduct requires
further study.
Despite quantitative modification, we were unable to obtain
crystallographic data of HR45-modified saFabH. We modelled
the adduct by docking the recent crystal structure of HR45 30
into the active site of saFabH31 (PDB: 3IL7) guided by our pro-
posed mechanism (Fig. S2 and S4†). Although there is ample
space for HR45 in the active site, the catalytically essential
residue C112 has little freedom of movement, limiting the likely
positions of the ligand and suggesting possible hydrogen
bonding between the C-5 oxygen of HR45 and the side chain of
the catalytically essential N268.29 This model could be a starting
point to develop highly specific inhibitors targeting FabH.32
Fig. 3 Purified tryptic peptide (103-VASMDQLAACSGFMYSMITAK-123) in (a) ammonium acetate (100 mM, pH 7.0) for 16 h at 37 °C and (b)
ammonium bicarbonate (100 mM, pH 8.0) for 16 h at 37 °C. The purified peptide modified with HR45 in (c) ammonium acetate (100 mM, pH 7.0) for
16 h at 37 °C, and (d) in ammonium bicarbonate (100 mM, pH 8.0) for 16 h at 37 °C. All masses were observed within 15 ppm of expected.
Fig. 4 The EICs of C112-containing peptides after pepsin digest. Left: Unmodified saFabH with expanded MS spectra of two separate unmodified
peptides. Right: HR45-modified saFabH with expanded MS spectra of two separate modified peptides. Note the appearance of the chlorine isotope
pattern in both modified ions.
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Conclusions
We have shown that the 1,2-dithiol-3-one HR45 covalently
modifies saFabH through a Michael-type addition elimination
at the catalytic residue C112. We suggest that this is also the
mode of inhibition of the molecule on other FabH isoforms,
and potentially other systems including the inhibition of
ecMurA by HR12. We have also shown that the reason that this
covalent modification has previously escaped detection is that
under normal tryptic digest conditions the alkaline hydrolysis
pathway of HR45 facilitates the conversion of the C112 to Dha,
the mechanism of which remains to be determined.
Describing the precise mode of action of molecules isolated
from screening campaigns that failed to make the clinic may
have impact on the design and discovery of new antimicrobial
leads.24 Our detailed mechanistic study of HR45 provides
insight for the design of new antimicrobials, and this
approach will no doubt be useful for other systems.
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